# Administrative-Core-001

> **NIH NIH P01** · UNIVERSITY OF WISCONSIN-MADISON · 2022 · $70,033

## Abstract

PROJECT SUMMARY (same as CA250972)
This Program Project grant will establish the fully integrated interdisciplinary programs of research and core
facilities that are necessary to develop a fundamental understanding of the complex interplay between two
rapidly emerging fields in cancer therapy: 1) targeted radionuclide therapy (TRT) and 2) immunotherapy. Our
overarching objectives are to develop a detailed mechanistic understanding of the immunomodulatory capacity
of TRT agents and to evaluate and compare the ability of these agents to elicit cooperative therapeutic
interactions in combination with immunotherapies. To achieve this, we will employ a representative variety of
TRT agents to deliver radiation in vivo using clinically relevant murine tumor models and companion canines
that have spontaneously developed cancers. We will determine the precise dosimetry for each radionuclide-,
TRT vector-, and tumor model. This will facilitate studies of dose-, dose-rate-, and dose-range-dependent
effects on the host immune system, tumor infiltrating immune cells, cytokine expression in the tumor
microenvironment, immune susceptibility of tumor cells, mechanisms of immune suppression, and the
development of antigenspecific adaptive immunity. We will determine the functional consequences of these
effects by testing the broad hypothesis that, by modulating tumor immune tolerance and functional
immunogenicity at all tumor sites, TRT will increase response to certain cancer immunotherapies. We will test
this in the following Program Projects: Project 1: Novel TRTs for Dosimetry-Guided Immunomodulation,
Project 2: TRT to enhance tumor cell immune susceptibility and response to immune checkpoint inhibitors,
Project 3: Combining TRT with a localized in situ vaccine to overcome immune suppression in the tumor
microenvironment and augment T cell responses, Project 4: TRT with tumor-specific vaccine to stimulate and
expand T-cell activation. These highly integrated projects will not only benefit from the methods and findings
generated in one another, but they also will directly benefit from the expertise and service of four essential
Core Facilities: 1) Advanced imaging and dosimetry core (AIDC), 2) Radiopharmaceutical and radiochemistry
core (RPRC), 3) Biostatistics and bioinformatics core (BBC), and 4) Administrative core. Complementing these
are robust institutional facilities that will enable successful completion of our proposed studies. Our
multidisciplinary team brings together the broad expertise needed to mobilize these resources in pursuit of our
proposed objectives. These efforts will further benefit from robust institutional matching support, leadership of a
strong Internal Advisory Committee, invaluable Industry collaborations, and expertise of an External Advisory
Board. Because of the immediate and broad potential for clinical translation of our results, these studies
portend an opportunity to improve the treatment of any oncology patient, regardless ...

## Key facts

- **NIH application ID:** 10707579
- **Project number:** 3P01CA250972-03S1
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** Zachary Scott Morris
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $70,033
- **Award type:** 3
- **Project period:** 2022-06-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10707579

## Citation

> US National Institutes of Health, RePORTER application 10707579, Administrative-Core-001 (3P01CA250972-03S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10707579. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*